Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 721 | 683 |
| Cost of other revenues | 17 | 18 |
| Selling, general and administrative | 861 | 867 |
| Research and development | 163 | 143 |
| Amortization of intangible assets | 241 | 256 |
| Goodwill impairments | 1,426 | — |
| Restructuring, integration and separation costs | 13 | 1 |
| Other expense, net | 32 | 15 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's R&D?
- Bausch Health Companies (BHC) reported R&D of $163M in Q1 2026.
- How has Bausch Health Companies's R&D changed year-over-year?
- Bausch Health Companies's R&D increased by 14.0% year-over-year, from $143M to $163M.
- What is the long-term trend for Bausch Health Companies's R&D?
- Over 4 years (2021 to 2025), Bausch Health Companies's R&D has grown at a 7.8% compound annual growth rate (CAGR), from $465M to $629M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Bausch Health Companies's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude